Who are Caffeine citrate oral solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Caffeine Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/caffeine-citrate-oral-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Caffeine citrate oral solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Caffeine citrate oral solution (Caffeine citrate oral solution) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Adenosine receptor antagonist; methylxanthine. Area: Neonatology; Respiratory.

marketed Adenosine receptor antagonist; methylxanthine Adenosine receptors (A1, A2A) Neonatology; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Caffeine citrate oral solution (Caffeine citrate oral solution) — NICHD Global Network for Women's and Children's Health. Caffeine citrate is a nonselective adenosine receptor antagonist that blocks adenosine-mediated central nervous system depression, promoting wakefulness and respiratory stimulation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Caffeine citrate oral solution TARGET	Caffeine citrate oral solution	NICHD Global Network for Women's and Children's Health	marketed	Adenosine receptor antagonist; methylxanthine	Adenosine receptors (A1, A2A)
Caffeine Pill	Caffeine Pill	Rothman Institute Orthopaedics	phase 3	Adenosine receptor antagonist	Adenosine receptors (A1, A2A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Adenosine receptor antagonist; methylxanthine class)

NICHD Global Network for Women's and Children's Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caffeine citrate oral solution — Competitive Intelligence Brief. https://druglandscape.com/ci/caffeine-citrate-oral-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing